Evidence digest
What the research on Thymosin Alpha-1 actually shows
The indexed literature on Thymosin Alpha-1 includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Thymosin Alpha-1 is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 4 studies indexed · 4 human · compound record
- Studies indexed
- 4
- Human evidence
- 4
- Preclinical only
- 0
What is and is not established
What the literature supports
- Human clinical or observational records are indexed for Thymosin Alpha-1 (4).
- Published research is indexed back to 1979, with roughly 864 PubMed records located.
- It is listed by one or more vendors tracked in this index.
What is NOT established
- This index does not evaluate whether Thymosin Alpha-1 is safe or effective for any use.
- Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
- No dosing, protocol or human-use guidance is provided or implied anywhere in this index.
Studies indexed
2 human — controlled trial · 1 systematic review · 1 meta-analysis
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trialBMJ (Clinical research ed.) · 2025 | Human — controlled trial | Not recorded | — | To evaluate whether the immunomodulatory drug thymosin α1 reduces mortality in adults with sepsis. Multicentre, double blinded, placebo controlled phase 3 trial. 22 centres in China, September 2016 to December 2020. 1106 adults aged 18-85 years with a diagnosis of sepsis according to sepsis-3 criteria and randomly assigned in a 1:1 ratio to receive thymosin α1 (n=552) or placebo (n=554). A stratified block method was used for randomisation, and participants were s… | PMID 39814420 |
| Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trialBMC medicine · 2026 | Human — controlled trial | Not recorded | — | Neoadjuvant immunochemotherapy has emerged as a promising strategy for locally advanced gastric and gastroesophageal junction (G/EGJ) adenocarcinoma, but a substantial proportion of patients derive limited benefit. Thymalfasin is an immunomodulatory peptide that may amplify antitumor immunity while attenuating toxicity. We conducted a phase II trial to evaluate anti-PD-1 plus SOX (S-1 and oxaliplatin) immunochemotherapy combined with thymalfasin as neoadjuvant treatment for G… | PMID 41749205 |
| Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical TrialsAlternative therapies in health and medicine · 2024 | Systematic review | Not recorded | — | This study aims to assess the safety and efficacy of Thymosin Alpha 1 (Tα1) through a comprehensive narrative review of clinical studies involving over 11 000 human subjects in more than 30 trials. The focus was on Tα1's application in COVID-19, autoimmune conditions, and cancer treatment, with implications for future considerations. We systematically searched articles relevant to critical studies on COVID-19, infectious diseases, cancer, and autoimmune diseases i… | PMID 38308608 |
| Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trialsFrontiers in cellular and infection microbiology · 2025 | Meta-analysis | Not recorded | — | Despite advances in understanding sepsis pathophysiology and extensive research, few treatments effectively target its underlying immune dysfunction. Thymosin α1 (Tα1) shows promise as an immunomodulator, but its impact on sepsis remains unclear. A search strategy was designed to include any prospective clinical studies using Tα1 for assessing 28-day mortality in patients with sepsis, excluding combination therapy studies. We conducted trial sequential analy… | PMID 40969554 |
Vendors listing Thymosin Alpha-1
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Polaris Peptides | 93.877% | 0 | profile → |
| Next Gen Peptides | 93.897% | 2 | profile → |
| PeptidePlugs | 89.790% | 2 | profile → |
| American Peptides | 83.6100% | 1 | profile → |
| Northline Labs | 79.493% | 0 | profile → |
| Good Science Bio | 79.275% | 0 | profile → |
| Ascension Peptides | 78.186% | 1 | profile → |
| Licensed Peptides | 7789% | 1 | profile → |
| Modern Aminos | 74100% | 2 | profile → |
| Simple Peptide | 7489% | 1 | profile → |
| BioLongevity Labs | 67.274% | 0 | profile → |
| Mile High Compounds | 65.494% | 0 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.